120 related articles for article (PubMed ID: 30696805)
1. CDC37 as a novel target for the treatment of NPM1-ALK expressing anaplastic large cell lymphomas.
Kuravi S; Parrott E; Mudduluru G; Cheng J; Ganguly S; Saunthararajah Y; Jensen RA; Blagg BS; McGuirk JP; Balusu R
Blood Cancer J; 2019 Jan; 9(2):14. PubMed ID: 30696805
[No Abstract] [Full Text] [Related]
2. IL10RA modulates crizotinib sensitivity in NPM1-ALK+ anaplastic large cell lymphoma.
Prokoph N; Probst NA; Lee LC; Monahan JM; Matthews JD; Liang HC; Bahnsen K; Montes-Mojarro IA; Karaca-Atabay E; Sharma GG; Malik V; Larose H; Forde SD; Ducray SP; Lobello C; Wang Q; Luan SL; Pospíšilová Š; Gambacorti-Passerini C; Burke GAA; Pervez S; Attarbaschi A; Janíková A; Pacquement H; Landman-Parker J; Lambilliotte A; Schleiermacher G; Klapper W; Jauch R; Woessmann W; Vassal G; Kenner L; Merkel O; Mologni L; Chiarle R; Brugières L; Geoerger B; Barbieri I; Turner SD
Blood; 2020 Oct; 136(14):1657-1669. PubMed ID: 32573700
[TBL] [Abstract][Full Text] [Related]
3. Advances in understanding the pathogenesis of systemic anaplastic large cell lymphomas.
Boi M; Zucca E; Inghirami G; Bertoni F
Br J Haematol; 2015 Mar; 168(6):771-83. PubMed ID: 25559471
[TBL] [Abstract][Full Text] [Related]
4. Inhibitors of the anaplastic lymphoma kinase.
Mologni L
Expert Opin Investig Drugs; 2012 Jul; 21(7):985-94. PubMed ID: 22612599
[TBL] [Abstract][Full Text] [Related]
5. Anaplastic lymphoma kinase as a therapeutic target in anaplastic large cell lymphoma, non-small cell lung cancer and neuroblastoma.
Cheng M; Ott GR
Anticancer Agents Med Chem; 2010 Mar; 10(3):236-49. PubMed ID: 20406193
[TBL] [Abstract][Full Text] [Related]
6. Distribution of NPM1-ALK and X-ALK fusion transcripts in paediatric anaplastic large cell lymphoma: a molecular-histological correlation.
Damm-Welk C; Klapper W; Oschlies I; Gesk S; Röttgers S; Bradtke J; Siebert R; Reiter A; Woessmann W
Br J Haematol; 2009 Aug; 146(3):306-9. PubMed ID: 19545284
[TBL] [Abstract][Full Text] [Related]
7. Antitumor activity of pyridoisoquinoline derivatives F91873 and F91874, novel multikinase inhibitors with activity against the anaplastic lymphoma kinase.
Kruczynski A; Mayer P; Marchand A; Vispé S; Fournier E; Annereau JP; Brel V; Barret JM; Delsol G; Imbert T; Fahy J; Bailly C
Anticancer Drugs; 2009 Jun; 20(5):364-72. PubMed ID: 19322071
[TBL] [Abstract][Full Text] [Related]
8. ALK kinase domain mutations in primary anaplastic large cell lymphoma: consequences on NPM-ALK activity and sensitivity to tyrosine kinase inhibitors.
Lovisa F; Cozza G; Cristiani A; Cuzzolin A; Albiero A; Mussolin L; Pillon M; Moro S; Basso G; Rosolen A; Bonvini P
PLoS One; 2015; 10(4):e0121378. PubMed ID: 25874976
[TBL] [Abstract][Full Text] [Related]
9. Evidence Suggesting That Discontinuous Dosing of ALK Kinase Inhibitors May Prolong Control of ALK+ Tumors.
Amin AD; Rajan SS; Liang WS; Pongtornpipat P; Groysman MJ; Tapia EO; Peters TL; Cuyugan L; Adkins J; Rimsza LM; Lussier YA; Puvvada SD; Schatz JH
Cancer Res; 2015 Jul; 75(14):2916-27. PubMed ID: 26018086
[TBL] [Abstract][Full Text] [Related]
10. Silibinin suppresses NPM-ALK, potently induces apoptosis and enhances chemosensitivity in ALK-positive anaplastic large cell lymphoma.
Molavi O; Samadi N; Wu C; Lavasanifar A; Lai R
Leuk Lymphoma; 2016 May; 57(5):1154-62. PubMed ID: 26133723
[TBL] [Abstract][Full Text] [Related]
11. Detection of a TRAF1-ALK fusion in an anaplastic large cell lymphoma patient with chemotherapy and ALK inhibitor-resistant disease.
Lawrence K; Berry B; Handshoe J; Hout D; Mazzola R; Morris SW; Saltman DL
BMC Res Notes; 2015 Jul; 8():308. PubMed ID: 26187744
[TBL] [Abstract][Full Text] [Related]
12. Treatment of Refractory ALK Rearranged Anaplastic Large Cell Lymphoma With Alectinib.
Reed DR; Hall RD; Gentzler RD; Volodin L; Douvas MG; Portell CA
Clin Lymphoma Myeloma Leuk; 2019 Jun; 19(6):e247-e250. PubMed ID: 30992232
[No Abstract] [Full Text] [Related]
13. New avenues for targeted therapies and biomarkers in anaplastic large cell lymphoma.
Egger G; Turner SD
Epigenomics; 2017 Feb; 9(2):97-100. PubMed ID: 28097892
[No Abstract] [Full Text] [Related]
14. Optimizing treatment for patients with anaplastic lymphoma kinase-positive lung cancer.
Dagogo-Jack I; Shaw AT; Riely GJ
Clin Pharmacol Ther; 2017 May; 101(5):625-633. PubMed ID: 28182271
[TBL] [Abstract][Full Text] [Related]
15. Reversal of microRNA-150 silencing disadvantages crizotinib-resistant NPM-ALK(+) cell growth.
Hoareau-Aveilla C; Valentin T; Daugrois C; Quelen C; Mitou G; Quentin S; Jia J; Spicuglia S; Ferrier P; Ceccon M; Giuriato S; Gambacorti-Passerini C; Brousset P; Lamant L; Meggetto F
J Clin Invest; 2015 Sep; 125(9):3505-18. PubMed ID: 26258416
[TBL] [Abstract][Full Text] [Related]
16. Crizotinib in anaplastic large-cell lymphoma.
Gambacorti-Passerini C; Messa C; Pogliani EM
N Engl J Med; 2011 Feb; 364(8):775-6. PubMed ID: 21345110
[No Abstract] [Full Text] [Related]
17. The t(2;5) in human lymphomas.
Kadin ME; Morris SW
Leuk Lymphoma; 1998 Apr; 29(3-4):249-56. PubMed ID: 9684923
[TBL] [Abstract][Full Text] [Related]
18. Translocations and mutations involving the nucleophosmin (NPM1) gene in lymphomas and leukemias.
Falini B; Nicoletti I; Bolli N; Martelli MP; Liso A; Gorello P; Mandelli F; Mecucci C; Martelli MF
Haematologica; 2007 Apr; 92(4):519-32. PubMed ID: 17488663
[TBL] [Abstract][Full Text] [Related]
19. [Clinicopathologic features of 66 cases of anaplastic lymphoma kinase positive and negative systemic anaplastic large cell lymphoma: a comparative study].
Shi Y; Chen G; Zhou XG; Gong LP; Yu R; Zheng YY; Xie JL; Jin Y
Zhonghua Bing Li Xue Za Zhi; 2010 Apr; 39(4):235-9. PubMed ID: 20654121
[TBL] [Abstract][Full Text] [Related]
20. The role of anaplastic lymphoma kinase inhibitors in the treatment of advanced nonsmall cell lung cancer.
D'Arcangelo M; Wynes MW; Hirsch FR
Curr Opin Oncol; 2013 Mar; 25(2):121-9. PubMed ID: 23385859
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
